OncoMatch/Clinical Trials/NCT06834529
CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma
Is NCT06834529 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies non-drug interventions for relapsed or refractory b cell leukemia and lymphoma.
This is a single arm study to evaluate the safety and efficacy of CAR2219 CAR-T cells in the treatment of relapsed/refractory CD19/CD22 positive B cell Leukemia and Lymphoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Chronic Lymphocytic Leukemia
Biomarker criteria
Required: CD19 positive
Required: CD22 positive
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: rituximab or another anti-CD20 monoclonal antibody (rituximab) — B-cell lymphoma
Patients must have received rituximab or another anti-CD20 monoclonal antibody (unless Investigator determines that tumor is CD20-negative)
Must have received: anthracycline-containing chemotherapy regimen — B-cell lymphoma
Patients must have received...an anthracycline-containing chemotherapy regimen
Lab requirements
Blood counts
hgb≥70g/l
Kidney function
creatinine ≤1.5×uln
Liver function
total bilirubin ≤1.5×uln, alt and ast≤2.5×uln
Cardiac function
left ventricular ejection fraction≥50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06834529 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received rituximab or another anti-CD20 monoclonal antibody and anthracycline-containing chemotherapy regimen.
Does this trial require CD19?
Yes, CD19 positive is a required biomarker for enrollment.
Does this trial require CD22?
Yes, CD22 positive is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger and at least 14 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify